Inclusion Criteria:

- Signed informed consent, males or females aged 18 or older, LVEF ≤ 40% assessed by
RNVG or contrast ventriculogram or ≤ 35% assessed by TTE within the previous 6
months, LVEF < 45% as assessed by RNVG during Visit 1, NYHA Class II, III or IV
symptoms primarily related to heart failure, ischaemic and non-ischaemic patients and
on stable heart failure therapy as defined by physician's best practice.

Exclusion Criteria:

- Key exclusion criteria include acute myocarditis within the last 12 months, diabetes
mellitus not controlled by diet, oral therapy or insulin therapy, homozygous familial
hypercholesterolaemia, receiving biventricular pacing or expected to receive
biventricular pacing in the next 6 months, subjects who normally would be considered
for statin therapy in the next 6 months, sever hypertension, history of definite
myocardial infarction, cerebrovascular accident, percutaneous transluminal coronary
angioplasty or coronary bypass graft within 3 months prior to enrolment in the study,
body mass index < 15, plus others.